[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634815":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":61,"collaborators":63,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":19,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":19,"enrollmentInfo":75,"targetDuration":19,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":87,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Dispatch Biotherapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"DISP-10","EXPERIMENTAL","Participants will receive DV-10 in combination with ide-cel. Lymphodepleting chemotherapy (fludarabine and cyclophosphamide) will be administered a few days prior to ide-cel.",[13],"Biological: DISP-10",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce ide-cel.\n\nDuring ide-cel production, participants may receive bridging therapy for disease control per Investigator discretion.\n\nDV-10 administration will be followed by lymphodepleting chemotherapy (fludarabine and cyclophosphamide) and subsequent ide-cel administration.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Dispatch Clinical","CONTACT","(215) 792-4699","clinicaltrials@dispatchbio.com",[27,41,51],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":19},"City of Hope","RECRUITING","Duarte","California","91010","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-117.97729,34.13945,{"lat":39,"lon":38},{"facility":42,"status":29,"city":43,"state":44,"zip":45,"country":33,"countryCode":34,"cosmosGeoPoint":46,"geoPoint":50,"contacts":19},"University of Cincinnati Cancer Center","Cincinnati","Ohio","45267",{"type":36,"coordinates":47},[48,49],-84.51439,39.12711,{"lat":49,"lon":48},{"facility":52,"status":29,"city":53,"state":54,"zip":55,"country":33,"countryCode":34,"cosmosGeoPoint":56,"geoPoint":60,"contacts":19},"Tennessee Oncology","Nashville","Tennessee","37203",{"type":36,"coordinates":57},[58,59],-86.78444,36.16589,{"lat":59,"lon":58},{"type":62,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR",[64],{"name":65,"class":6},"Bristol-Myers Squibb","100634815","phase-1-a-phase-1-study-evaluating-disp-10-in-participants-with-advanced-gastrointestinal-cancers-100634815",false,"NCT07544589","A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers","A Phase 1 Study to Evaluate the Safety and Efficacy of DISP-10 in Participants With Advanced Gastrointestinal Cancers","Key Inclusion Criteria:\n\n1. Histologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, or colorectal adenocarcinoma\n2. Measurable disease according to RECIST v1.1 and at least 1 additional site of disease amenable to biopsy\n3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n4. Aged ≥18 years at time of signing informed consent\n5. Adequate organ function\n\nKey Exclusion Criteria:\n\n1. Previous solid organ or hematopoietic cell transplant\n2. Evidence of rapid disease progression, defined as radiographic or clinical progression within 3 months of the most recent prior line of therapy\n3. Known history of hepatitis B or HIV infection\n4. Previous or concurrent malignancy except if curatively treated more than 3 years prior to enrollment\n5. Known active central nervous system (CNS) metastases\n6. Clinically significant pleural or pericardial effusion or peritoneal carcinomatosis\n7. Active treatment with antiviral agents\n8. History of severe hypersensitivity to fludarabine or cyclophosphamide\n9. Prior therapies\u002Ftreatments with oncolytic viruses or T cell derived cellular therapy","ALL","18 Years",{"count":76,"type":77},66,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor \\[CAR\\] T), in adult participants with advanced gastrointestinal (GI) cancers.\n\nThe study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.",[83,84,85,86],"Colorectal Cancer","Gastric Adenocarcinoma","Esophageal Adenocarcinoma","Gastroesophageal Adenocarcinoma",[88,89,90,91,92,93],"CAR T","Adenovirus","ABECMA","BCMA","gastrointestinal cancer","CAR-T","2026-05-27",{"date":96,"type":97},"2026-05-29","ACTUAL",{"date":99,"type":77},"2026-04",{"date":101,"type":77},"2046-04",{"name":5,"class":6},3]